RESVERLOGIX

www.resverlogix.com

Suite 202
279 Midpark Way SE
Calgary AB T2X 1M2
P 403.254.9252
F 403.256.8495
info@resverlogix.com

For Immediate Release TSX Exchange Symbol: **RVX**

Resverlogix Corp. Announces First Administration in Man Trial

CALGARY, AB, September 11, 2006 – Resverlogix Corp. ("Resverlogix") (TSX: RVX), is pleased to announce today that it has chosen lead molecules for first administration in man studies. The pharmacokinetic results of the molecule(s) in humans will guide and accelerate the further clinical development as to pharmacological doses needed to significantly raise ApoA-I, the core protein in the good cholesterol (HDL). Administration of low doses, so called microdosing, is a highly attractive technique for pharmaceutical companies which can improve predictability, efficiency and expedience of subsequent human trials.

"Choosing our lead molecules for the first administration in man studies represents a major scientific step in our exciting path of development for our NexVas™ PR program", stated Don McCaffrey President and CEO of Resverlogix. "We expect that by as early as Q1 2007 the study will have shown that the successful results from our animal models are representative for humans helping us to predict the ApoA-I raising properties in humans. First administration into man has always been stated as a key milestone and our unique business model focuses on creating expedited value early in a product's life cycle. By providing consistent animal proof of concept data and early human data we have been able to further our business discussions making NexVas™ a highly attractive project for early partnership with a leading global pharmaceutical company," added McCaffrey.

"Microdosing using sub-pharmacological doses is based on sensitive AMS (accelerator mass spectrometry) analysis and has proven to be a useful tool for clinical development. The first administration in man will take the development to the next level by delineating similarities and differences between animal study results and the behavior of the molecules in man", stated Dr. Jan Johansson Senior Vice President Clinical Affairs at Resverlogix.

About Resverlogix

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the risk of Cardiovascular Disease (CVD). Through successful research efforts, the Company has expanded its CVD platform to three programs, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (NexVas PR**),** is the Company's primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI) is the Company's second CVD program, a discovery stage technology focused on molecular targets of vascular inflammation. ReVas™ the Company's third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered ReVas™ with Medtronic Inc., a world leading medical technology company. The Company's secondary focus is TGF-β Shield**™**, a program that aims to address the unmet medical need of grievous diseases, such as cancer and fibrosis, with a TGF- β inhibitor. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Kenneth Lebioda
Senior Vice President
Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252 ext. 227
Fax: 403-256-8495
Email: ken@resverlogix.com

Theresa Kennedy
Vice President
Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Website: www.resverlogix.com